Showing results (261-270 of 335) with videos related to

Sort By:
Pageof 34
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2018
First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid TumorsJohn H Strickler, Colin D Weekes, John Nemunaitis, et al.
Seminars in Oncology|October 3, 2003
Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working groupChris H Takimoto, Scot C Remick, Sunil Sharma, et al.
Cancer Chemotherapy and Pharmacology|September 1, 2005
Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancersRamesh K Ramanathan, Marwan Fakih, Sridhar Mani, et al.
Oncogene|February 23, 2016
Threonine 209 phosphorylation on RUNX3 by Pak1 is a molecular switch for its dualistic functionsA Kumar, M Singhal, C Chopra, et al.
Investigational New Drugs|March 1, 2006
Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypesWilliam C Zamboni, Ramesh K Ramanathan, Howard L McLeod, et al.
Genome Medicine|February 4, 2014
STAG2 is a clinically relevant tumor suppressor in pancreatic ductal adenocarcinomaLisa Evers, Pedro A Perez-Mancera, Elizabeth Lenkiewicz, et al.
British Journal of Cancer|September 27, 2017
Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumoursJeffrey R Infante, Ronald L Korn, Lee S Rosen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2008
A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignanciesSuresh S Ramalingam, Merrill J Egorin, Ramesh K Ramanathan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2007
Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignanciesSuresh S Ramalingam, Robert A Parise, Ramesh K Ramanathan, et al.
Cancer Chemotherapy and Pharmacology|January 27, 2009
A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancerRamesh K Ramanathan, Chandra P Belani, Deepti A Singh, et al.
Pageof 34